Geron Netherlands

Company snapshot

Geron Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Myelofibrosis, Myelodysplastic syndromes (MDS). NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (3).

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Geron Netherlands. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Geron Netherlands.

1. Jun 8, 2026 Clinical update

   GRN163LMYF3001 — Phase 3

2. Jun 8, 2026 Clinical update

   63935937MDS3001 — Phase 3

3. May 26, 2026 Clinical update

   Imetelstat — Phase 3

View all clinical trial activity →

• What is Geron Netherlands?

  Geron Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Myelofibrosis, Myelodysplastic syndromes (MDS). NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Clini

• Is Geron Netherlands publicly traded?

  Geron Netherlands appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Geron Netherlands develop or market?

  We link 2 drug profile(s) where Geron Netherlands is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/geron-netherlands-b-v#company-drugs.

• What are the latest developments for Geron Netherlands?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Geron Netherlands focus on?

  Geron Netherlands focuses on Myelofibrosis, Myelodysplastic syndromes (MDS) based on our analysis of their pipeline programs and drug development activities.